Publications by authors named "N Fakas"

Article Synopsis
  • A study was conducted to test the validity and reliability of the Greek version of the Migraine-Specific Quality of Life Questionnaire (MSQv.2.1) among 141 Greek adults with migraines and 135 control participants.
  • The results showed strong internal consistency across the questionnaire's three dimensions (Role Restrictive, Role Preventive, and Emotional Function), with high reliability and confirmed factor structure through statistical analysis.
  • Significant differences were found between migraineurs and controls, indicating poorer quality of life for those with migraines, highlighting the MSQv.2.1-GR as a valid tool for assessing migraine-related quality of life in Greece.
View Article and Find Full Text PDF

Objective: To estimate the prevalence and burden of medication overuse headache in a representative sample of the Greek population, aged 18-70 years old.

Methods: This is a cross-sectional descriptive observational study performed by quantitative computer-assisted telephone interviews, using a standardized 37-item questionnaire for headaches. The prevalence of medication overuse headache was estimated in the general population and compared within the groups formed by factors such as age, gender, diagnosis of headache type, prophylactic treatment used, geographical regions, social class, workdays lost and loss of productivity.

View Article and Find Full Text PDF

Introduction: Fingolimod is the first approved oral therapy for relapsing-remitting multiple sclerosis (RRMS). The present study aimed to further characterize fingolimod's safety profile, and to assess the patient-reported treatment satisfaction and impact of fingolimod on the quality of life (QoL) of patients with multiple sclerosis (MS) treated in routine care in Greece.

Methods: This was a multicenter, prospective, observational, 24-month study conducted in Greece by hospital-based and private practice neurologists who specialize in MS.

View Article and Find Full Text PDF

High-dose intravenous steroid treatment (HDIST) represents the first choice of treatment for multiple sclerosis (MS) relapses. Chronic oral glucocorticoid (GC) administration correlates with bone loss whereas data regarding HDIST in MS are still conflicting. Twenty-five newly diagnosed MS patients (NDMSP) (median age: 37 years) were prospectively studied for the effects of HDIST on bone mineral density (BMD) and bone metabolism.

View Article and Find Full Text PDF